TICKERNERD
Menu
VYGRVYGRHealthcare · Biotechnology

VYGR Stock Forecast: Voyager Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$3.27
+1.55% on the day

The 11 Wall Street analysts covering Voyager Therapeutics, Inc. hold a median 12-month price target of $12 — +267.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 15 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$201.5M
Ticker Nerd rank
74 / 100
Median analyst target
$12
Analysts covering
11
Total return, dividends reinvested
1W
0.0%
1M
+3.5%
YTD
−16.8%
1Y
−12.1%
From 52W high
−38.6%
From 52W low
+9.0%
$3.00
$5.33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VYGR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Voyager Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
82
Volatility
77
Size
69
Issuance
65
Revisions
64
Accruals
55
Value
52
Quality
49
Momentum
43

Growth (82): Sales and profits are climbing, and climbing faster than before.

Momentum (43): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VYGR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VYGR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26VYGRHigh $25Median $12Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $8Median $12High $25

The green dot is the last close — the median target sits +267.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Aug 2026HC Wainwright & Co.ReiteratesBuy$25
17 Mar 2026HC Wainwright & Co.ReiteratesBuy$25
17 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025WedbushMaintainsOutperform—
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025Canaccord GenuityMaintainsBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025Cantor FitzgeraldReiteratesOverweight—
12 Mar 2025WedbushReiteratesOutperform—
12 Mar 2025Wells FargoMaintainsOverweight—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
27 Jan 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025Cantor FitzgeraldInitiatesOverweight—
2 Dec 2024CitigroupInitiatesBuy—
14 Nov 2024Canaccord GenuityMaintainsBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
16 Oct 2024Leerink PartnersInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VYGR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VYGR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Voyager Therapeutics, Inc. (VYGR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
6.1×

Cheaper than 65% of US stocks

Price / sales
5.8×

Cheaper than 22% of US stocks

Price / book
1.1×

Cheaper than 70% of US stocks

EV / EBITDA
−1.1×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
−39.1%

Higher than 7% of US stocks

Earnings growth (YoY)
−39.1%

Higher than 13% of US stocks

Gross margin
—
Operating margin
−833.9%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−54.1%

Higher than 20% of US stocks

Return on assets
−27.3%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VYGR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VYGRVoyager Therapeutics, Inc.$201.5M
74
ABOSAcumen Pharmaceuticals, Inc.$192.8M
42
KRROKorro Bio, Inc.$191.5M
29
KROSKeros Therapeutics, Inc.$199.1M
68
CRBPCorbus Pharmaceuticals Holdings, Inc.$186.9M
26
DTILPrecision BioSciences, Inc.$205.1M
70
PEPGPepGen Inc.$205.5M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Voyager Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VYGR news & analysis

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 7 Aug 2026positive

Voyager Therapeutics reported a second-quarter loss of $0.40 per share, narrower than the Zacks Consensus Estimate of a $0.55 loss and improved from a $0.57 loss a year earlier. The company missed revenue estimates for the quarter.

Why it matters — The narrower-than-expected quarterly loss indicates recent performance was better than analysts anticipated on the bottom line, which a VYGR watcher would track against consensus expectations.

FAQ

Frequently asked questions about VYGR stock

What is the VYGR stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Voyager Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $8 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VYGR stock a buy right now?

Of the 11 analysts covering Voyager Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Voyager Therapeutics, Inc. 74 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VYGR?

As at 15 Aug 2026, Voyager Therapeutics, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).

Will VYGR stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +267.0% from the last close, and Ticker Nerd's factor model ranks Voyager Therapeutics, Inc. 74 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VYGR stock forecast for 2030?

No analyst covering Voyager Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VYGR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $25 over the next 12 months.

How has VYGR stock performed over the past year?

Voyager Therapeutics, Inc. returned -12.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Voyager Therapeutics, Inc. do?

Voyager Therapeutics Inc. operates as a biotechnology company focusing on developing gene therapies for severe neurological diseases and other disorders.

What is the latest news on VYGR?

The most recent item we track (Zacks Investment Research, 7 Aug 2026): "Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates". Voyager Therapeutics reported a second-quarter loss of $0.40 per share, narrower than the Zacks Consensus Estimate of a $0.55 loss and improved from a $0.57 loss a year earlier. The company missed revenue estimates for the quarter.

Company

About Voyager Therapeutics, Inc.

Voyager Therapeutics Inc. operates as a biotechnology company focusing on developing gene therapies for severe neurological diseases and other disorders. The company's primary purpose is to harness the potential of gene therapy to transform the treatment landscape for conditions that have limited therapeutic options, such as Parkinson’s disease, Huntington’s disease, and various forms of neuropathy. Notable features of Voyager Therapeutics include its robust pipeline of preclinical and clinical-stage programs that utilize its proprietary AAV capsid engineering and delivery technology. This technology aims to optimize the targeting and expression of therapeutic genes in specific areas of the central nervous system. As an integral player in the biotech industry, Voyager Therapeutics contributes significant advancements in the field of precision medicine, offering potential new avenues for treatment where conventional methods may fall short. Headquartered in Cambridge, Massachusetts, the company positions itself at the forefront of therapeutic innovation, collaborating with leading pharmaceutical companies to accelerate the development and commercialization of groundbreaking therapies.

CEO Dr. Alfred W. Sandrock Jr., M.D., Ph.D. · 141 employees · United States · https://www.voyagertherapeutics.com